kyvero
Log in Sign up free
Market leaders

BLLN

BillionToOne, Inc. (BLLN)

Healthcare • Diagnostics & Research

StockNasdaqGSUnited StatesUS0901681058

105.33 USD -4.92% today Updated 13 Nov 2026 16:26
Follow it for free

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by BillionToOne, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 03 Mar 2027 in 110 days · 16:00 · estimate 0.25
Last results 0.48 vs 0.30 estimated 04 Nov 2026 · Beat +58.9%
Beat the estimate 3 of 4 1 missed · 0 in line · 2 beats in a row
Average surprise +160.3% reported against the estimate, last 4 quarters

Earnings per share: estimate and reported

09 Dec 2025: estimate 0.16 09 Dec 2025: reported 0.91 12/25 04 Mar 2026: estimate 0.17 04 Mar 2026: reported 0.15 03/26 05 Aug 2026: estimate 0.16 05 Aug 2026: reported 0.36 08/26 04 Nov 2026: estimate 0.30 04 Nov 2026: reported 0.48 11/26

Estimate Reported: beat Reported: miss In line

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
03 Mar 2027 16:00 0.25 — — Upcoming
04 Nov 2026 16:00 0.30 0.48 +58.9% Beat
05 Aug 2026 16:00 0.16 0.36 +124.3% Beat
04 Mar 2026 16:00 0.17 0.15 -10.6% Miss
09 Dec 2025 16:00 0.16 0.91 +468.8% Beat

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2025 305.1M — 7.5M 2.4% 0.14 +113.3% 15.7M
2024 — — — — -1.05 +49.7% —
2023 — — — — -2.10 — —

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month
Price history in USD, by week
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
09 Nov 2026 – 13 Nov 2026 In progress 114.12 117.97 104.35 105.33 -7.55% 3,306,057
02 Nov 2026 – 06 Nov 2026 113.17 114.91 100.15 113.94 +0.55% 4,256,300
26 Oct 2026 – 30 Oct 2026 108.00 119.20 106.29 113.32 +5.15% 2,281,700
19 Oct 2026 – 23 Oct 2026 98.95 108.99 98.23 107.77 +9.83% 2,099,000
12 Oct 2026 – 16 Oct 2026 97.61 102.93 90.48 98.12 +0.03% 2,612,100
05 Oct 2026 – 09 Oct 2026 105.15 112.87 91.01 98.09 -7.37% 2,916,500
28 Sep 2026 – 02 Oct 2026 120.64 125.00 102.91 105.90 -13.96% 2,757,600
21 Sep 2026 – 25 Sep 2026 106.61 127.71 102.75 123.08 +16.20% 3,456,200
14 Sep 2026 – 18 Sep 2026 98.00 113.00 97.99 105.92 +7.24% 3,685,000
08 Sep 2026 – 11 Sep 2026 99.24 102.98 95.22 98.77 -0.62% 2,284,600
44 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close
110.79 USD
Market cap
5.3B
Exchange
NasdaqGS
Country
United States
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 8.8 / 25 No figures for this part: it counts as a cautious 35%. —
Quality Return on equity, net margin and how stable the margins are. 14.7 / 25
  • ROE of 13%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 16.9 / 20
  • Net debt is -8.1× EBITDA
  • Free cash flow yield of 0.2%
Valuation Free cash flow yield and the P/E against its sector. 0.3 / 15
  • P/E 121.7 against 30.6 for its sector
Analysts How far the analysts' average target is from today's price. 10.0 / 10
  • Analysts' target is +23% from the price

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C).

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
FigureValueReading Sector median
P/E (trailing) 121.74× Weak 30.56×
P/E (forward) 75.42× Weak 14.16×
Price / book 10.68× Weak 3.5×
Price / sales 12.25× Weak 3.33×
EV / EBITDA 95.08× Weak 11.19×
Free cash flow yield 0.2% Weak 2.1%
Quality
FigureValueReading Sector median
Gross margin 71.4% Good 54.9%
Operating margin 9% Fair 5.8%
Net margin 10.5% Good 1.2%
Return on equity 13.2% Fair 4.4%
Return on assets 5.1% Fair 2.7%
Financial health
FigureValueReading Sector median
Debt / equity 0.25× Good 0.4×
Net debt / EBITDA -8.11× Good 1.46×
Interest cover 168.66× Good 2.17×
Current ratio 11.25× Good 2.64×
Dividends
FigureValueReading Sector median
Payout of earnings 0% Weak 0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow BLLN and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in

Cookies — We use a few cookies to make the site work. With your OK we also measure how the public pages are used (Google Analytics) and may show advertising. You can change this at any time. More details